{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:40:08Z","timestamp":1759009208246,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.jinf.2015.04.021","type":"journal-article","created":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T15:30:35Z","timestamp":1429889435000},"page":"S15-S20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["Group B meningococcal vaccine science and policy"],"prefix":"10.1016","volume":"71","author":[{"given":"Simon B.","family":"Drysdale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2015.04.021_bib1","unstructured":"Public Health England. Invasive meningococcal infections laboratory reports in England and Wales, by capsular group & epidemiological year, 1998\/99\u20132012\/13. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/343375\/Table_1a_Invasive_meningococcal__E_W_by_capsular_group___epi_year.pdf. [accessed 29.09.2014]."},{"issue":"3","key":"10.1016\/j.jinf.2015.04.021_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/adc.80.3.290","article-title":"Emergency management of meningococcal disease","volume":"80","author":"Pollard","year":"1999","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.jinf.2015.04.021_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00006454-199305000-00008","article-title":"Outcomes of bacterial meningitis in children: a meta-analysis","volume":"12","author":"Baraff","year":"1993","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.jinf.2015.04.021_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1042\/CS20090513","article-title":"Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease","volume":"118","author":"Hill","year":"2010","journal-title":"Clin Sci"},{"issue":"4","key":"10.1016\/j.jinf.2015.04.021_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1128\/CMR.7.4.559","article-title":"Current status of meningococcal group B vaccine candidates: capsular or noncapsular?","volume":"7","author":"Diaz Romero","year":"1994","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jinf.2015.04.021_bib6","first-page":"101","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines","volume":"31","author":"Trotter","year":"2007","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.jinf.2015.04.021_bib7","unstructured":"Public Health England. Invasive meningococcal infections laboratory reports in England and Wales by capsular group & calendar year, 1998-2013. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/343395\/Table_4a_Invasive_meningococcal__E_W_by_capsular_group___year.pdf. [accessed 29.09.2014]."},{"issue":"1","key":"10.1016\/j.jinf.2015.04.021_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2334-12-35","article-title":"Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands","volume":"12","author":"Kaaijk","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2015.04.021_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.3.3.157","article-title":"The influence of active normal serum (Complement) upon meningococci: I. The opsonic activity of fresh normal serum alone and in combination with antimeningitis serum for meningococci","volume":"3","author":"Kolmer","year":"1918","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2015.04.021_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4049\/jimmunol.3.3.201","article-title":"The relation of the meningococcidal activity of the blood to resistance to virulent meningococci","volume":"3","author":"Matsunami","year":"1918","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2015.04.021_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4049\/jimmunol.3.3.177","article-title":"The influence of active normal serum (Complement) upon meningococci: II. The bactericidal and protective value of fresh Normal serum alone and in combination with antimeningitis serum for meningococci","volume":"3","author":"Matsunami","year":"1918","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2015.04.021_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.7.1.1","article-title":"Study of the virulence of meningococci for man and of human susceptibility to meningococcic infection","volume":"7","author":"Heist","year":"1922","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.jinf.2015.04.021_bib13","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the menongococcus I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.jinf.2015.04.021_bib14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"9431","key":"10.1016\/j.jinf.2015.04.021_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jinf.2015.04.021_bib16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2015.04.021_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0b013e318224fb14","article-title":"Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine","volume":"30","author":"De Whalley","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.jinf.2015.04.021_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/archdischild-2013-303893","article-title":"Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination","volume":"98","author":"De Whalley","year":"2013","journal-title":"Arch Dis Child"},{"issue":"7659","key":"10.1016\/j.jinf.2015.04.021_bib19","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2015.04.021_bib20","unstructured":"Public Health England. Invasive meningococcal C infections laboratory reports in England and Wales by age group & epidemiological year, 1998\/99\u20132012\/13. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/343401\/Table_8a_Invasive_meningococcal_C__E_W_by_age_group___epi_year.pdf. [accessed 29.09.2014]."},{"issue":"2","key":"10.1016\/j.jinf.2015.04.021_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(09)70324-X","article-title":"Serogroup B meningococcal vaccines-an unfinished story","volume":"10","author":"Sadarangani","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2015.04.021_bib22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1473-3099(13)70341-4","article-title":"A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2015.04.021_bib23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3201\/eid1004.030247","article-title":"PorA variable regions of Neisseria meningitidis","volume":"10","author":"Russell","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2015.04.021_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.inf.0000258697.05341.2c","article-title":"New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16\u201324 months","volume":"26","author":"Wong","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"5459","key":"10.1016\/j.jinf.2015.04.021_bib25","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1126\/science.287.5459.1809","article-title":"Complete genome sequence of Neisseria meningitidis serogroup B strain MC58","volume":"287","author":"Tettelin","year":"2000","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.jinf.2015.04.021_bib26","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2009.12.027","article-title":"Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates","volume":"28","author":"Pajon","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jinf.2015.04.021_bib27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2958.2004.04423.x","article-title":"Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells","volume":"55","author":"Capecchi","year":"2005","journal-title":"Mol Microbiol"},{"issue":"21","key":"10.1016\/j.jinf.2015.04.021_bib28","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2009.02.098","article-title":"Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus","volume":"27","author":"Bambini","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jinf.2015.04.021_bib29","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.jinf.2015.04.021_bib30","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1128\/IAI.00466-06","article-title":"Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac","volume":"74","author":"Findlow","year":"2006","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.jinf.2015.04.021_bib31","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"45","key":"10.1016\/j.jinf.2015.04.021_bib32","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.jinf.2015.04.021_bib33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"9869","key":"10.1016\/j.jinf.2015.04.021_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jinf.2015.04.021_bib35","first-page":"573","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules","volume":"307","author":"Gossger","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2015.04.021_bib36","unstructured":"Public Health England. JCVI statement on MenB. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/294245\/JCVI_Statement_on_MenB.pdf. [accessed 29.09.2014]."},{"key":"10.1016\/j.jinf.2015.04.021_bib37","unstructured":"Public Health England. Invasive meningococcal B infections laboratory reports in England and Wales by age group & epidemiological year, 1998\/99\u20132012\/13. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/343400\/Table_7a_Invasive_meningococcal_B__E_W_by_age_group___epi_year.pdf. [accessed 29.09.2014]."},{"issue":"5","key":"10.1016\/j.jinf.2015.04.021_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(14)70027-1","article-title":"Hospital admission rates for meningitis and septicaemia caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae in children in England over five decades: a population-based observational study","volume":"14","author":"Martin","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"15","key":"10.1016\/j.jinf.2015.04.021_bib39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"Can Med Assoc J"},{"issue":"11","key":"10.1016\/j.jinf.2015.04.021_bib40","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"9960","key":"10.1016\/j.jinf.2015.04.021_bib41","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jinf.2015.04.021_bib42","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2015.04.021_bib43","unstructured":"Centers for Disease Control and Prevention. Serogroup B meningococcal vaccine & outbreaks. Available from: http:\/\/www.cdc.gov\/meningococcal\/outbreaks\/vaccine-serogroupb.html. [accessed 29.09.2014]."}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445315001140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445315001140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:21:53Z","timestamp":1759008113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445315001140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":43,"alternative-id":["S0163445315001140"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2015.04.021","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Group B meningococcal vaccine science and policy","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2015.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}